Overview

Immune Spatial Features of Guselkumab Cutaneous Response

Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Janssen Scientific Affairs, LLC